NEW YORK, May 5 (GenomeWeb News) – Cepheid announced yesterday that its Q1 revenues increased 3 percent to $20.2 million from $19.6 million during the year-ago period, while its net loss grew 9.3 percent to $6.7 million from $3.5 million during the first quarter of 2005. Research and development costs grew 2.9 percent to $5.8 million from $4.5 million during the first quarter of 2005. As of March 31, Cepheid had $59.7 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.